$384 Million is the total value of Integral Health Asset Management, LLC's 71 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 62.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CNC | Sell | CENTENE CORP DEL | $12,629,000 | -31.9% | 150,000 | -33.3% | 3.29% | -35.9% |
| NVST | Sell | ENVISTA HOLDINGS CORPORATION | $12,178,000 | -9.9% | 250,000 | -16.7% | 3.17% | -15.3% |
| SAGE | Sell | SAGE THERAPEUTICS INC | $10,294,000 | -40.8% | 311,000 | -24.0% | 2.68% | -44.4% |
| AMED | Sell | AMEDISYS INC | $6,892,000 | -14.9% | 40,000 | -20.0% | 1.79% | -20.0% |
| BIIB | Sell | BIOGEN INC | $3,159,000 | -62.4% | 15,000 | -57.1% | 0.82% | -64.6% |
| APLS | Sell | APELLIS PHARMACEUTICALS INC | $2,021,000 | -64.4% | 39,769 | -66.9% | 0.53% | -66.5% |
| PTCT | Sell | PTC THERAPEUTICS INC | $1,567,000 | -12.6% | 42,000 | -6.7% | 0.41% | -17.7% |
| INCY | Sell | INCYTE CORP | $1,430,000 | -35.1% | 18,000 | -40.0% | 0.37% | -38.9% |
| RETA | Sell | REATA PHARMACEUTICALS INCcl a | $1,147,000 | -57.8% | 35,000 | -66.0% | 0.30% | -60.4% |
| DNLI | Sell | DENALI THERAPEUTICS INC | $836,000 | -81.3% | 26,000 | -74.0% | 0.22% | -82.3% |
| Sell | AVALO THERAPEUTICS INC | $507,000 | -81.7% | 700,000 | -56.9% | 0.13% | -82.7% | |
| MYOV | Exit | MYOVANT SCIENCES LTD | $0 | – | -25,000 | -100.0% | -0.11% | – |
| AMRN | Exit | AMARIN CORP PLCspons adr new | $0 | – | -200,000 | -100.0% | -0.19% | – |
| LXRX | Exit | LEXICON PHARMACEUTICALS INC | $0 | – | -200,000 | -100.0% | -0.22% | – |
| LYEL | Exit | LYELL IMMUNOPHARMA INC | $0 | – | -140,000 | -100.0% | -0.30% | – |
| IMGN | Exit | IMMUNOGEN INC | $0 | – | -250,000 | -100.0% | -0.51% | – |
| MGNX | Exit | MACROGENICS INC | $0 | – | -130,000 | -100.0% | -0.58% | – |
| Exit | BRIDGEBIO PHARMA INCcall | $0 | – | -150,000 | -100.0% | -0.69% | – | |
| MASI | Exit | MASIMO CORP | $0 | – | -10,000 | -100.0% | -0.81% | – |
| HZNP | Exit | HORIZON THERAPEUTICS PUB L | $0 | – | -30,000 | -100.0% | -0.90% | – |
| ARWR | Exit | ARROWHEAD PHARMACEUTICALS IN | $0 | – | -50,000 | -100.0% | -0.92% | – |
| ALNY | Exit | ALNYLAM PHARMACEUTICALS INC | $0 | – | -20,000 | -100.0% | -0.94% | – |
| GSK | Exit | GLAXOSMITHKLINE PLCsponsored adr | $0 | – | -100,000 | -100.0% | -1.22% | – |
| EW | Exit | EDWARDS LIFESCIENCES CORP | $0 | – | -45,000 | -100.0% | -1.61% | – |
| LH | Exit | LABORATORY CORP AMER HLDGS | $0 | – | -20,000 | -100.0% | -1.74% | – |
| ABBV | Exit | ABBVIE INC | $0 | – | -50,000 | -100.0% | -1.87% | – |
| FATE | Exit | FATE THERAPEUTICS INC | $0 | – | -130,000 | -100.0% | -2.10% | – |
| ABT | Exit | ABBOTT LABS | $0 | – | -70,000 | -100.0% | -2.73% | – |
| MCK | Exit | MCKESSON CORP | $0 | – | -55,000 | -100.0% | -3.78% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CYTOKINETICS INC | 15 | Q3 2023 | 4.7% |
| SAGE THERAPEUTICS INC | 15 | Q2 2023 | 5.0% |
| BIOMARIN PHARMACEUTICAL INC | 15 | Q2 2023 | 4.1% |
| ENVISTA HOLDINGS CORPORATION | 14 | Q3 2023 | 4.0% |
| AKERO THERAPEUTICS INC | 14 | Q3 2023 | 1.5% |
| REVVITY INC | 13 | Q3 2023 | 4.2% |
| BLUEPRINT MEDICINES CORP | 13 | Q3 2023 | 3.3% |
| PTC THERAPEUTICS INC | 13 | Q2 2023 | 1.7% |
| ELEVANCE HEALTH INC | 12 | Q3 2023 | 6.7% |
| NEVRO CORP | 12 | Q4 2022 | 4.5% |
View Integral Health Asset Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-09 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-03 |
| 13F-HR | 2022-05-12 |
| 13F-HR | 2022-02-02 |
| 13F-HR | 2021-11-12 |
View Integral Health Asset Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.